First transgenic primate model created for hepatitis B research
Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...
idw8d
Hepatitis D: When the immune system gets out of control
Infection with hepatitis D viruses causes severe inflammation of the liver. An MHH team has now identified a marker on natural killer cells that is influenced by the anti-inflammatory effectiveness of ...
Healio28d
People with HBV, HIV coinfection at risk for hepatitis D ‘superinfection’
Source: Adobe Stock. “Therefore, we reevaluated the incidence and outcomes of hepatitis D virus infection among PWH in Taiwan,” Huang said. The researchers conducted a retrospective study ...
Metro US on MSN10d
City releases report on Hepatitis, encourages residents to get tested
The Philadelphia Department of Public Health has released its 2023 Annual Report on Hepatitis B, C, and D in the city. The ...
Armed robbery in Revesby1d
Scientists Create First Hepatitis B Transgenic Model
The genetically modified animal model could lead to new treatments for the global disease Lauren Rust, Ph.D., assistant staff ...
Bluejay Therapeutics Appoints Mary Cromwell as Senior Vice President and Head of Technical Operations
Bluejay’s lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).
Healio13d
Viral hepatitis elimination requires equitable public health approach
Viral hepatitis is a major danger to public health. According to WHO’s 2024 Global Hepatitis Report, viral hepatitis deaths ...
clinicaladvisor.com13d
Brelovitug Granted Breakthrough Designation for Chronic Hepatitis Delta
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).
idw7d
Hepatitis D: When the immune system gets out of control
Hepatitis D viruses (HDV) cause the most severe form of chronic, virus-related hepatitis. The active ingredient bulevirtide has been on the European market since mid-2023 as the only approved ...